The content is available as a PDF (156.8 KB).
Bibliografía
- 1.Langman M.J., Jensen D.M., Watson D.J., Harper S.E., Zhao P-L., Quan H. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA. 1999;282:1929–1933. doi: 10.1001/jama.282.20.1929. [DOI] [PubMed] [Google Scholar]
- 2.Goldstein J.L., Silvestein F.E., Agrawal N.M., Hubbard R.C., Kaiser J., Maurath Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol. 2000;95:1681–1690. doi: 10.1111/j.1572-0241.2000.02194.x. [DOI] [PubMed] [Google Scholar]
- 3.Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., Pincus T., Whelton A. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoartrhitis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA. 2000;284:1247–1255. doi: 10.1001/jama.284.10.1247. [DOI] [PubMed] [Google Scholar]
- 4.Bombardier C., Laine L., Reich A., Reicin A., Shapiro D., Burgos-Vargas R., for the VIGOR Study Group Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520–1528. doi: 10.1056/NEJM200011233432103. [DOI] [PubMed] [Google Scholar]
- 5.Mukherjee D., Nissen S.E., Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286:954–959. doi: 10.1001/jama.286.8.954. [DOI] [PubMed] [Google Scholar]
- 6.Anónimo In focus: rofecoxib (Vioox) Current Problems in Pharmacovigilance. 2000;26:13. [Google Scholar]
- 7.Anónimo Celecoxib (CelebrexTM): 1 year later. Canadian ADR Newsletter. 2000;10:1–3. [Google Scholar]
- 8.Anónimo Celecoxib: early australian reporting experience. Aust Adverse Drug React Bull. 2000;19:6–7. [Google Scholar]